PAG
CBIO

Private Advisor Group’s Crescent Biopharma CBIO Stock Holding History

Private Advisor Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20
Closed -$8K – 2332
2020
Q2 		$8K Buy
+20
New +$5.66K ﹤0.01% 3024

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisor Group's CBIO Position: Q3 2020 in Review

Private Advisor Group sold out of Crescent Biopharma (CBIO) in Q3 2020, closing a stake of 20 shares — an estimated $8K sold.

Private Advisor Group first reported a position in CBIO in Q2 2020 and held it in 1 quarter. The position peaked at $8K in Q2 2020. 80 funds tracked by Wall St. Rank hold CBIO as of Q3 2020.

  • Private Advisor Group reported no remaining Crescent Biopharma position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 20 Crescent Biopharma shares in Q3 2020, an estimated $8K.
  • Private Advisor Group first reported a position in Crescent Biopharma in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Crescent Biopharma position peaked at $8K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.